Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 4, 2008, Pages 335-339

  Andrés, Raquel ^a   Mayordomo, Jose I ^a   Visus, Carmen ^a   Isla, Dolores ^a   Godino, Javier ^a   Escudero, Pilar ^a   Saenz, Alberto ^a   Ortega, Eugenia ^a   Lastra, Rodrigo ^a   Lambea, Julio ^a   Aguirre, Elena ^a   Elosegui, Luis ^a   Marcos, Ivan ^a   Manuel, Ruiz Echarri ^a   Millastre, Esther ^a   Berta, Sàez Gutierrez ^a   Asin, Laura ^a   Vidal, Maria J ^a   Ferrer, Ana ^a   Giner, Armando ^a   Larrad, Luis ^a   Carapeto, Francisco J ^a   Tres, Alejandro ^a   more..

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Melanoma; RT PCR; S 100 protein; Tyrosinase

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PROTEIN S 100; RNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; BLOOD; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SKIN TUMOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 55449093264     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318162f11e     Document Type: Article

References (37)

1. Roses DF, Karp NS, Oratz R, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet. 1991;172:252-258.
2. Provost N, Marghoob AA, Kopf AW, et al. Laboratory test and imaging studies in patients with cutaneous malignant melanoma: a survey of experienced physicians. J Am Acad Dermatol. 1997;36:711-720.
3. Smith B, Selby P, Southgate J. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and poly-merase chain reaction. Lancet. 1991;338:1227-1229.
4. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178:489-495.
5. Kunter U. Buer J, Probst M, et al. Peripheral Blood tyrosinase messenger RNA detection and survival in malignat melanoma. J Natl Cancer Inst.1996;88:590-594.
6. Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemol Biomarkers Prev. 1996;5:293-296.
7. Pittman K, Burchill S, Smith B, et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol. 1996;7:297-301.
8. Jung FA, Buzaid AC, Ross MI, et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997;15:2826-2831.
9. Glaser R, Rass K, Seiter S, et al. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients. A clinical two-center study. J Clin Oncol. 1997;15:2818-2825.
10. Reinhlod U, Ludtke Handjery HC, Schnautz S, et al. The analysis of tyrosinase specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol. 1997;108:166-169.
11. Aubin F, Chtourou M, Teyssier JR, et al. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival. Melanoma Res. 2000;10:113-118.
12. Abraha HD, Fuller LC, Do Vivier AW, et al. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol. 1991;137:381-385.
13. Buer J, Probst M, Franzke A, et al. Elevated serum levels of S-100 and survival in metastatic malignant melanoma. Br J Cancer. 1997;75:1373-1376.
14. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer. 1995; 31:924-928.
15. Henze G, Dummer F, Joller-Jemelka HI, et al. Serum S-100-a marker for disease monitoring in metastaic melanoma. Dermatology. 1997;194: 208-212.
16. Von Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 1996;6:133-137.
17. Deichmann M, Brenner A, Bock M, et al. S-100-beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from non progressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891-1896.
18. Schittek B, Blaheta HJ, Ellwanger U, et al. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. Recent Results Cancer Res. 2001;158:93-104.
19. Ghossein RA, Bhattacharya S, Coit DG. Reverse transcriptase polymerase chain reaction (RT-PCR). Detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? Recent Results Cancer Res. 2001; 158:63-77.
20. Jackal A, Diechman M, Waldmann V, et al. S-100β protein in serum, a tumor marker in malignant melanoma-current state of knowledge and clinical experiences. Hautarzt. 1999;50:250-256.
21. Donato R. Perspectives in S-100 protein biology. Cell Calcium. 1991; 12:713-726.
22. Baudier J, Briving C, Deinum J, et al. Effect of S-100 proteins and calmodulin on Ca2+-induced disassembly of brain microtubule-protein in vitro. FEBS Lett. 1982;147:165-167.
23. Engelkamp D, Schafer B, Mattei M, et al. Six S-100 genes are clustered on human chromosome 1q21: identification of two genes coding for the two previously unreported calcium binding proteins S-100D and S-100E. Proc Natl Acad Sci USA. 1993;90:6547-6551.
24. Huang C, Provost N, Marghoob A, et al. Laboratory test and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol. 1988;39:451-463.
25. Schultz ES, Diepgen TL, von den Driesch P. Clinical and prognostic relevance of serum S-100B protein in malignant melanoma. Br J Dermatol. 1998;138:426-430.
26. Kaskel P, Berking C, Sander S, et al. S-100 protein in perpheral blood: a marker for melanoma metastases. J Am Acad Dermatol. 1999;41:962-969.
27. Bonfer J, Korse C, Nieweg O, et al. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100β it's a prognostic value in malignant melanoma. Br J Cancer. 1998;77:2210-2214.
28. Schmitz C, Brenner W, Henze E, et al. Compaartive study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 2000;20:5059-5063.
29. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S-100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol. 2000;143:269-274.
30. Hauschild A, Michaelsen J, Brenner W, et al. Prognostic significance of serum S-100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 1999;9:155-161.
31. Curry BJ, Farrelly M, Hersey P. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma: Melanoma Res. 1999;9:557-567.
32. Màrtenson ED, Hansson LO, Nilsson B, et al. Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824-831.
33. Mohammed MQ, Abraha HD, Sherwood RA, et al. Serum S-100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol. 2001;18:109-120.
34. Krahn G, Kaskel P, Sander S, et al. S-100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21:1311-1316.
35. Hauschlid A, Engel G, Brenner W, et al. Predictive value of serum S-100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol. 1999;140:1065-1071.
36. Juergensen A, Holzapfel U, Hein R, et al. Comparison of two prognostic markers for malignant melanoma: MIA and S-100 beta. Tumour Biol. 2001;22:54-58.
37. Acland K, Evans AV, Abraha H, et al. Serum S-100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol. 2002;146:832-835.